Connect Biopharma Holdings Ltd (NASDAQ:CNTB) announced that enrollment for its Phase 2 Seabreeze STAT Asthma study has been completed. The trial evaluates rademikibart, an anti‑interleukin‑4‑receptor alpha antibody, as an adjunct to standard of care for acute exacerbations in asthma patients with type 2 inflammation. The company also indicated that enrollment for its Seabreeze STAT COPD study is on track to be completed within the current month. Topline data from the asthma study are expected in early September 2026, with COPD study results to follow thereafter. Connect Biopharma intends to meet with the U.S. Food and Drug Administration later in 2026 to seek alignment on a subsequent Phase 3 development program based on the forthcoming readouts. The firm highlighted a strong balance sheet, stating that its cash resources provide a runway extending into the second half of 2027. Following the enrollment announcement, the company's shares rose approximately 8% on the trading day.